The effect of CSD on PFS and overall survival (OS) in patients with EGFR-mutated lung adenocarcinoma is yet to be clarified, and only few studies have directly focused on the relationship between the efficacy of EGFR-TKI and CSD in patients with EGFR-mutated lung adenocarcinoma. Here, EGFR is linked to lung adenocarcinoma.